OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Oncotelic Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.02+0.00 (+11.45%)
Close on Oct 19, 2026
- Market cap
- $8.66M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Oncotelic Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.46M | $166.30M |
| Enterprise Value | $7.16M | $88.19M |
| PE Ratio | 0.03 | 20.44 |
| PB Ratio | 0.03 | 2.03 |
| P/TBV Ratio | 0.03 | 2.29 |
Income (trailing twelve months)
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$3.19M | -$21.40M |
| Pretax Income | $360.58M | -$14.34M |
| Net Income | $249.30M | -$22.46M |
| EBITDA | -$3.19M | -$16.91M |
| EPS (Diluted) | $0.59 | -$0.83 |
Returns
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 182.7% | -53.2% |
| Return on Assets (ROA) | 118.3% | -40.9% |
| Return on Invested Capital (ROIC) | -1.60% | -32.4% |
| Return on Capital Employed (ROCE) | -0.85% | -38.1% |
Growth
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| EPS Growth (3Y CAGR) | 289.3% | -0.17% |
Balance sheet
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $186.01K | $61.43M |
| Net Cash (Debt) | $186.01K | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $264.56M | $49.09M |
| Book Value Per Share | $0.58 | $1.37 |
| Tangible Book Value | $261.77M | $23.52M |
| Working Capital | -$16.45M | $76.81M |
Financial position
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.08 | 3.34 |
| Quick Ratio | 0.01 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.38M | -$12.35M |
Efficiency
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | $9.59M | -$703.34K |
| Employee Count | 26 | 74 |
Dividends and yields
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 2945.4% | -23.3% |
Shares
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 457,513,000 | 58,127,000 |
| Shares Change (YoY) | 4.41% | 10.9% |
| Shares Change (QoQ) | 2.89% | 0.54% |
| Float | 317,735,000 | 49,136,700 |
| Shares Held by Insiders | 30.6% | 11.6% |
Taxes
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Income Tax | $111.55M | $79.87K |
| Effective Tax Rate | 30.9% | 20.6% |
Scores
| Measure | Oncotelic Therapeutics | Industry median |
|---|---|---|
| Graham Number | $2.77 | $18.73 |
| Graham Upside | 14876.4% | -45.1% |
| Altman Z-Score | 0.70 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Oncotelic Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.